Basket cover image
15 handpicked stocks

American Manufacturing's $550B Boost

A new trade agreement between the U.S. and Japan establishes a 15% tariff on Japanese imports and secures a $550 billion investment in American industries. This deal creates a growth opportunity for domestic manufacturers and automotive suppliers set to benefit from the major industrial investment.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 24

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

GM

General Motors Co.

GM

Current price

$57.06

F

Ford Motor Co.

F

Current price

$11.58

LEA

Lear Corp.

LEA

Current price

$103.07

About This Group of Stocks

1

Our Expert Thinking

The landmark U.S.-Japan trade agreement creates a massive $550 billion investment opportunity in American manufacturing. This deal avoids a disruptive trade war while providing a clear runway for industrial expansion, particularly benefiting companies in the automotive supply chain and manufacturing value chain.

2

What You Need to Know

This group focuses on U.S. manufacturers and suppliers positioned to directly benefit from foreign direct investment. These companies are integral to domestic production capacity expansion, factory upgrades, and the automotive sector's growth under government-backed industrial revitalization.

3

Why These Stocks

Each stock was handpicked by professional analysts based on their strategic position within the U.S. manufacturing ecosystem. These companies are specifically positioned to absorb the new wave of investment and benefit from increased production capacity in the automotive and industrial sectors.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+13.72%

Group Performance Snapshot

13.72%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 13.72% over the next year.

11 of 14

Stocks Rated Buy by Analysts

11 of 14 assets in this group are rated Buy by professional analysts.

12.4% vs 4%

Group Growth vs Bank interest

This group averaged a 12.4% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🚀

Massive Investment Wave Coming

A historic $550 billion investment is flowing into American manufacturing, creating unprecedented growth opportunities for companies positioned in the right sectors.

🏭

Government-Backed Industrial Boom

This isn't just market speculation - it's a government-supported industrial revitalization that could transform domestic manufacturing capacity and drive sustained growth.

Trade War Fears Turned to Opportunity

What could have been a disruptive trade conflict became a landmark deal, removing uncertainty and creating a clear path for manufacturing expansion and investor confidence.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.